pembrolizumab + epirubicin + cyclophosphamide

Pembrolizumab + epirubicin + cyclophosphamide is a combination regimen used primarily in the treatment of early-stage or locally advanced triple-negative breast cancer (TNBC), particularly as a neoadjuvant (pre-surgical) therapy. **Pembrolizumab** is a monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance anti-tumor immune response. **Epirubicin** is an anthracycline chemotherapeutic agent that intercalates into DNA and inhibits topoisomerase II, causing cytotoxicity in rapidly dividing cells. **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to cell death. The combination aims to improve pathological complete response rates and event-free survival in patients with high-risk, early-stage TNBC. This regimen is often administered intravenously and is being studied and used clinically for neoadjuvant and adjuvant therapy in breast cancer[2][5][7][8].